Bruce D Walker

List of Publications by Year
in descending order

222 papers	37,460 citations	2963 93 h-index	3173 186 g-index
256 all docs	256 docs citations	256 times ranked	29337 citing authors

#	Article	IF	Citations
1	PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 2006, 443, 350-354.	13.7	2,380
2	Vigorous HIV-1-Specific CD4+ T Cell Responses Associated with Control of Viremia. Science, 1997, 278, 1447-1450.	6.0	1,780
3	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. Science, 2010, 330, 1551-1557.	6.0	1,054
4	Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding. Science, 2011, 333, 1633-1637.	6.0	1,046
5	HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature, 1998, 391, 397-401.	13.7	950
6	Immune control of HIV-1 after early treatment of acute infection. Nature, 2000, 407, 523-526.	13.7	939
7	CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature Medicine, 2007, 13, 46-53.	15.2	910
8	Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature, 2004, 432, 769-775.	13.7	784
9	SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications, 2020, 11, 5493.	5.8	702
10	Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nature Genetics, 2007, 39, 733-740.	9.4	691
11	Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature, 2015, 522, 487-491.	13.7	665
12	Human Immunodeficiency Virus Controllers: Mechanisms of Durable Virus Control in the Absence of Antiretroviral Therapy. Immunity, 2007, 27, 406-416.	6.6	646
13	Loss of Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell, 2020, 183, 143-157.e13.	13.5	599
14	Cervicovaginal Bacteria Are a Major Modulator of Host Inflammatory Responses in the Female Genital Tract. Immunity, 2015, 42, 965-976.	6.6	554
15	Evolution and transmission of stable CTL escape mutations in HIV infection. Nature, 2001, 412, 334-338.	13.7	523
16	Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science, 2020, 370, .	6.0	511
17	HIV infection is blocked in vitro by recombinant soluble CD4. Nature, 1988, 331, 76-78.	13.7	497
18	Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity, 2017, 46, 29-37.	6.6	488

#	Article	IF	Citations
19	A soluble CD4 protein selectively inhibits HIV replication and syncytium formation. Nature, 1988, 331, 78-81.	13.7	468
20	Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1. Journal of Virology, 2006, 80, 3617-3623.	1.5	408
21	Adaptation of HIV-1 to human leukocyte antigen class I. Nature, 2009, 458, 641-645.	13.7	408
22	Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nature Medicine, 2007, 13, 100-106.	15.2	400
23	Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature, 2010, 467, 591-595.	13.7	393
24	HIV-1 Integration Landscape during Latent and Active Infection. Cell, 2015, 160, 420-432.	13.5	393
25	HIV-1 persistence in CD4+ T cells with stem cellâ€“like properties. Nature Medicine, 2014, 20, 139-142.	15.2	379
26	Comprehensive serological profiling of human populations using a synthetic human virome. Science, 2015, 348, aaa0698.	6.0	364
27	Cellular Immune Responses and Viral Diversity in Individuals Treated during Acute and Early HIV-1 Infection. Journal of Experimental Medicine, 2001, 193, 169-180.	4.2	363
28	Influence of HLA-C Expression Level on HIV Control. Science, 2013, 340, 87-91.	6.0	352
29	A Blueprint for HIV Vaccine Discovery. Cell Host and Microbe, 2012, 12, 396-407.	5.1	348
30	Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature, 2011, 472, 495-498.	13.7	328
31	CXCL13 is a plasma biomarker of germinal center activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2702-2707.	3.3	322
32	Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic. JAMA Network Open, 2020, 3, e2030455.	2.8	315
33	Loss of HIV-1â€“specific CD8+ T Cell Proliferation after Acute HIV-1 Infection and Restoration by Vaccine-induced HIV-1â€“specific CD4+ T Cells. Journal of Experimental Medicine, 2004, 200, 701-712.	4.2	314
34	Influence of HLA-B57 on clinical presentation and viral control during acute HIV-1 infection. Aids, 2003, 17, 2581-2591.	1.0	309
35	Whole Genome Deep Sequencing of HIV-1 Reveals the Impact of Early Minor Variants Upon Immune Recognition During Acute Infection. PLoS Pathogens, 2012, 8, e1002529.	2.1	306
36	A genome-wide CRISPR screen identifies a restricted set of HIV host dependency factors. Nature Genetics, 2017, 49, 193-203.	9.4	290

#	Article	IF	Citations
37	Levels of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T-Lymphocyte Effector and Memory Responses Decline after Suppression of Viremia with Highly Active Antiretroviral Therapy. Journal of Virology, 1999, 73, 6721-6728.	1.5	287
38	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. PLoS Pathogens, 2010, 6, e1000917.	2.1	284
39	Relative Dominance of Gag p24-Specific Cytotoxic T Lymphocytes Is Associated with Human Immunodeficiency Virus Control. Journal of Virology, 2006, 80, 3122-3125.	1.5	275
40	HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8+ T Cell Response against HIV-1. PLoS Medicine, 2006, 3, e403.	3.9	273
41	Effects of thymic selection of the T-cell repertoire on HLA classâ€‰I-associated control of HIV infection. Nature, 2010, 465, 350-354.	13.7	269
42	HIV and HLA Class I: An Evolving Relationship. Immunity, 2012, 37, 426-440.	6.6	268
43	Immune Selection for Altered Antigen Processing Leads to Cytotoxic T Lymphocyte Escape in Chronic HIV-1 Infection. Journal of Experimental Medicine, 2004, 199, 905-915.	4.2	266
44	HLA-B57/B*5801 Human Immunodeficiency Virus Type 1 Elite Controllers Select for Rare Gag Variants Associated with Reduced Viral Replication Capacity and Strong Cytotoxic T-Lymphotye Recognition. Journal of Virology, 2009, 83, 2743-2755.	1.5	261
45	Clonal expansion of genome-intact HIV-1 in functionally polarized Th1 CD4+ T cells. Journal of Clinical Investigation, 2017, 127, 2689-2696.	3.9	249
46	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	13.7	245
47	Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. Journal of Virology, 2014, 88, 10056-10065.	1.5	242
48	Escape and Compensation from Early HLA-B57-Mediated Cytotoxic T-Lymphocyte Pressure on Human Immunodeficiency Virus Type 1 Gag Alter Capsid Interactions with Cyclophilin A. Journal of Virology, 2007, 81, 12608-12618.	1.5	241
49	Magnitude and Kinetics of CD8+ T Cell Activation during Hyperacute HIV Infection Impact Viral Set Point. Immunity, 2015, 43, 591-604.	6.6	234
50	Polyfunctional HIV-Specific Antibody Responses Are Associated with Spontaneous HIV Control. PLoS Pathogens, 2016, 12, e1005315.	2.1	220
51	Unravelling the mechanisms of durable control of HIV-1. Nature Reviews Immunology, 2013, 13, 487-498.	10.6	211
52	Translating HIV Sequences into Quantitative Fitness Landscapes Predicts Viral Vulnerabilities for Rational Immunogen Design. Immunity, 2013, 38, 606-617.	6.6	209
53	TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nature Immunology, 2012, 13, 691-700.	7.0	203
54	T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals. Cell, 2022, 185, 1041-1051.e6.	13.5	187

#	Article	IF	Citations
55	Coordinate linkage of HIV evolution reveals regions of immunological vulnerability. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11530-11535.	3.3	183
56	Persistent Lowâ€Level Viremia in HIVâ€1 Elite Controllers and Relationship to Immunologic Parameters. Journal of Infectious Diseases, 2009, 200, 984-990.	1.9	181
57	Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2014, 10, e1004287.	2.1	179
58	Human Immunodeficiency Virus Type 1-Specific CD8⁺T-Cell Responses during Primary Infection Are Major Determinants of the Viral Set Point and Loss of CD4⁺T Cells. Journal of Virology, 2009, 83, 7641-7648.	1.5	173
59	HIV-1-Specific Interleukin-21 ⁺ CD4 ⁺ T Cell Responses Contribute to Durable Viral Control through the Modulation of HIV-Specific CD8 ⁺ T Cell Function. Journal of Virology, 2011, 85, 733-741.	1.5	173
60	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	5.1	170
61	Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703â€“positive individuals and their transmission recipients. Journal of Experimental Medicine, 2009, 206, 909-921.	4.2	165
62	CD8+ T cells in HIV control, cure and prevention. Nature Reviews Immunology, 2020, 20, 471-482.	10.6	163
63	Marked Epitope- and Allele-Specific Differences in Rates of Mutation in Human Immunodeficiency Type 1 (HIV-1) Gag, Pol, and Nef Cytotoxic T-Lymphocyte Epitopes in Acute/Early HIV-1 Infection. Journal of Virology, 2008, 82, 9216-9227.	1.5	162
64	Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. Journal of Clinical Investigation, 2018, 128, 876-889.	3.9	157
65	Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. Journal of Experimental Medicine, 2012, 209, 1469-1479.	4.2	156
66	CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Journal of Clinical Investigation, 2011, 121, 1549-1560.	3.9	156
67	The T-Cell Response to HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007054-a007054.	2.9	155
68	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14658-14663.	3.3	154
69	Immune control of HIV: the obstacles of HLA and viral diversity. Nature Immunology, 2001, 2, 473-475.	7.0	153
70	Central Role of Reverting Mutations in HLA Associations with Human Immunodeficiency Virus Set Point. Journal of Virology, 2008, 82, 8548-8559.	1.5	152
71	Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood, 2011, 117, 3799-3808.	0.6	146
72	Definition of the viral targets of protective HIV-1-specific T cell responses. Journal of Translational Medicine, 2011, 9, 208.	1.8	143

#	Article	IF	Citations
73	Cutting Edge: Prolonged Exposure to HIV Reinforces a Poised Epigenetic Program for PD-1 Expression in Virus-Specific CD8 T Cells. Journal of Immunology, 2013, 191, 540-544.	0.4	143
74	A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2016, 12, e1005545.	2.1	142
75	A high-throughput single-cell analysis of human CD8+ T cell functions reveals discordance for cytokine secretion and cytolysis. Journal of Clinical Investigation, 2011, 121, 4322-4331.	3.9	140
76	Recommendations for analytical antiretroviral treatment interruptions in HIV research trialsâ€"report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	2.1	139
77	Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science, 2018, 359, 86-90.	6.0	135
78	The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. Journal of Infectious Diseases, 2018, 218, 1954-1963.	1.9	130
79	Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller. Science Translational Medicine, 2017, 9, .	5.8	128
80	HIV-1 Vpu Mediates HLA-C Downregulation. Cell Host and Microbe, 2016, 19, 686-695.	5.1	127
81	The Fitness Landscape of HIV-1 Gag: Advanced Modeling Approaches and Validation of Model Predictions by In Vitro Testing. PLoS Computational Biology, 2014, 10, e1003776.	1.5	125
82	Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity, 2016, 44, 391-405.	6.6	125
83	Antigen-Specific Antibody Glycosylation Is Regulated via Vaccination. PLoS Pathogens, 2016, 12, e1005456.	2.1	124
84	De Novo Generation of Escape Variant-Specific CD8 + T-Cell Responses following Cytotoxic T-Lymphocyte Escape in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2005, 79, 12952-12960.	1.5	122
85	Determinants of HIV-1 Mutational Escape From Cytotoxic T Lymphocytes. Journal of Experimental Medicine, 2003, 197, 1365-1375.	4.2	121
86	Nonprogressing HIV-infected children share fundamental immunological features of nonpathogenic SIV infection. Science Translational Medicine, 2016, 8, 358ra125.	5.8	121
87	Impaired Replication Capacity of Acute/Early Viruses in Persons Who Become HIV Controllers. Journal of Virology, 2010, 84, 7581-7591.	1.5	118
88	Recognition of a Defined Region within p24 Gag by CD8 + T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles. Journal of Virology, 2007, 81, 7725-7731.	1.5	116
89	HIV-specific CD8+ T cells and HIV eradication. Journal of Clinical Investigation, 2016, 126, 455-463.	3.9	116
90	HIV-1 Viral Escape in Infancy Followed by Emergence of a Variant-Specific CTL Response. Journal of Immunology, 2005, 174, 7524-7530.	0.4	109

#	Article	IF	Citations
91	Genetic interplay betweenHLA-CandMIR148Ain HIV control and Crohn disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20705-20710.	3.3	109
92	Resistance of HIV-infected macrophages to CD8+ T lymphocyteâ€"mediated killing drives activation of the immune system. Nature Immunology, 2018, 19, 475-486.	7.0	105
93	Structural topology defines protective CD8 ⁺ T cell epitopes in the HIV proteome. Science, 2019, 364, 480-484.	6.0	105
94	Nef-Mediated Resistance of Human Immunodeficiency Virus Type 1 to Antiviral Cytotoxic T Lymphocytes. Journal of Virology, 2002, 76, 1626-1631.	1.5	104
95	Profound Treg perturbations correlate with COVID-19 severity. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	104
96	Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nature Communications, 2016, 7, 11660.	5.8	103
97	Integrated single-cell analysis of multicellular immune dynamics during hyperacute HIV-1 infection. Nature Medicine, 2020, 26, 511-518.	15.2	100
98	HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. Aids, 2004, 18, 1383-1392.	1.0	99
99	Differences in the Selection Bottleneck between Modes of Sexual Transmission Influence the Genetic Composition of the HIV-1 Founder Virus. PLoS Pathogens, 2016, 12, e1005619.	2.1	97
100	Association between injectable progestin-only contraceptives and HIV acquisition and HIV target cell frequency in the female genital tract in South African women: a prospective cohort study. Lancet Infectious Diseases, The, 2016, 16, 441-448.	4.6	94
101	Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers. Journal of Virology, 2010, 84, 9463-9471.	1.5	92
102	Proliferative Capacity of Epitope-Specific CD8 T-Cell Responses Is Inversely Related to Viral Load in Chronic Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2007, 81, 434-438.	1.5	91
103	High frequency of rapid immunological progression in African infants infected in the era of perinatal HIV prophylaxis. Aids, 2007, 21, 1253-1261.	1.0	91
104	Low Levels of Peripheral CD161++CD8+ Mucosal Associated Invariant T (MAIT) Cells Are Found in HIV and HIV/TB Co-Infection. PLoS ONE, 2013, 8, e83474.	1.1	88
105	Gag-Protease-Mediated Replication Capacity in HIV-1 Subtype C Chronic Infection: Associations with HLA Type and Clinical Parameters. Journal of Virology, 2010, 84, 10820-10831.	1.5	87
106	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. Nature Immunology, 2019, 20, 824-834.	7.0	87
107	Rapid Definition of Five Novel HLA-Aâˆ—3002-Restricted Human Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Epitopes by Elispot and Intracellular Cytokine Staining Assays. Journal of Virology, 2001, 75, 1339-1347.	1.5	86
108	Impact of HLA-driven HIV adaptation on virulence in populations of high HIV seroprevalence. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5393-400.	3.3	85

#	Article	IF	Citations
109	Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes. PLoS Pathogens, 2015, 11, e1005285.	2.1	84
110	Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. Aids, 2008, 22, 1333-1343.	1.0	83
111	Elite Controllers with Low to Absent Effector CD8 ⁺ T Cell Responses Maintain Highly Functional, Broadly Directed Central Memory Responses. Journal of Virology, 2012, 86, 6959-6969.	1.5	83
112	LILRB2 Interaction with HLA Class I Correlates with Control of HIV-1 Infection. PLoS Genetics, 2014, 10, e1004196.	1.5	83
113	Differential Selection Pressure Exerted on HIV by CTL Targeting Identical Epitopes but Restricted by Distinct HLA Alleles from the Same HLA Supertype. Journal of Immunology, 2006, 177, 4699-4708.	0.4	79
114	Antigen-specific antibody Fc glycosylation enhances humoral immunity via the recruitment of complement. Science Immunology, 2018, 3, .	5.6	78
115	Elite control of HIV Infection: implications for vaccines and treatment. Topics in HIV Medicine: A Publication of the International AIDS Society, USA, 2007, 15, 134-6.	2.9	78
116	Potent Cell-Intrinsic Immune Responses in Dendritic Cells Facilitate HIV-1-Specific T Cell Immunity in HIV-1 Elite Controllers. PLoS Pathogens, 2015, 11, e1004930.	2.1	77
117	Detection and treatment of Fiebig stage I HIV-1 infection in young at-risk women in South Africa: a prospective cohort study. Lancet HIV,the, 2018, 5, e35-e44.	2.1	76
118	Mutually Exclusive T-Cell Receptor Induction and Differential Susceptibility to Human Immunodeficiency Virus Type 1 Mutational Escape Associated with a Two-Amino-Acid Difference between HLA Class I Subtypes. Journal of Virology, 2007, 81, 1619-1631.	1.5	75
119	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2016, 90, 2993-3002.	1.5	72
120	HIV Control Is Mediated in Part by CD8 ⁺ T-Cell Targeting of Specific Epitopes. Journal of Virology, 2014, 88, 12937-12948.	1.5	69
121	Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypes. Retrovirology, 2013, 10, 100.	0.9	68
122	Human Immunodeficiency Virus-Specific CD8⁺T-Cell Activity Is Detectable from Birth in the Majority of In Utero-Infected Infants. Journal of Virology, 2007, 81, 12775-12784.	1.5	67
123	HLA-Associated Viral Mutations Are Common in Human Immunodeficiency Virus Type 1 Elite Controllers. Journal of Virology, 2009, 83, 3407-3412.	1.5	67
124	The great escape â€“ AIDS viruses and immune control. Nature Medicine, 1999, 5, 1233-1235.	15.2	66
125	HLA-B*57 Micropolymorphism Shapes HLA Allele-Specific Epitope Immunogenicity, Selection Pressure, and HIV Immune Control. Journal of Virology, 2012, 86, 919-929.	1.5	66
126	Structure-guided TÂcell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell, 2021, 184, 4401-4413.e10.	13.5	65

#	Article	IF	Citations
127	Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection. PLoS Pathogens, 2015, 11, e1004954.	2.1	64
128	Antigen recognition-triggered drug delivery mediated by nanocapsule-functionalized cytotoxic T-cells. Biomaterials, 2017, 117, 44-53.	5.7	61
129	High-dimensional immunomonitoring models of HIV-1â€“specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood, 2013, 121, 801-811.	0.6	60
130	Dysfunctional HIV-Specific CD8+ T Cell Proliferation Is Associated with Increased Caspase-8 Activity and Mediated by Necroptosis. Immunity, 2014, 41, 1001-1012.	6.6	60
131	Antiviral CD8+ T Cells Restricted by Human Leukocyte Antigen Class II Exist during Natural HIV Infection and Exhibit Clonal Expansion. Immunity, 2016, 45, 917-930.	6.6	59
132	HIV Infection of Macrophages: Implications for Pathogenesis and Cure. Pathogens and Immunity, 2017, 2, 179.	1.4	59
133	Augmentation of HIV-specific T cell function by immediate treatment of hyperacute HIV-1 infection. Science Translational Medicine, 2019, 11, .	5.8	58
134	Killer cell immunoglobulinâ€“like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. Journal of Clinical Investigation, 2018, 128, 1903-1912.	3.9	52
135	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. Science Translational Medicine, 2021, 13, eabl4097.	5.8	52
136	Engineering modular intracellular protein sensor-actuator devices. Nature Communications, 2018, 9, 1881.	5.8	51
137	HIV-1 DNA sequence diversity and evolution during acute subtype C infection. Nature Communications, 2019, 10, 2737.	5.8	51
138	HLA tapasin independence: broader peptide repertoire and HIV control. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28232-28238.	3.3	51
139	Impact of HLA in Mother and Child on Disease Progression of Pediatric Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2009, 83, 10234-10244.	1.5	50
140	Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope. Journal of Virology, 2012, 86, 12643-12654.	1.5	49
141	CD8+ TCR Bias and Immunodominance in HIV-1 Infection. Journal of Immunology, 2015, 194, 5329-5345.	0.4	48
142	Broad and persistent Gag-specific CD8+ T-cell responses are associated with viral control but rarely drive viral escape during primary HIV-1 infection. Aids, 2015, 29, 23-33.	1.0	48
143	Moving ahead an HIV vaccine: Use both arms to beat HIV. Nature Medicine, 2011, 17, 1194-1195.	15.2	46
144	Frequencies of Circulating Th1-Biased T Follicular Helper Cells in Acute HIV-1 Infection Correlate with the Development of HIV-Specific Antibody Responses and Lower Set Point Viral Load. Journal of Virology, 2018, 92, .	1.5	46

#	Article	IF	Citations
145	Plasma CXCL13 but Not B Cell Frequencies in Acute HIV Infection Predicts Emergence of Cross-Neutralizing Antibodies. Frontiers in Immunology, 2017, 8, 1104.	2.2	45
146	Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection. BMC Medicine, 2020, 18, 81.	2.3	45
147	T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathogens, 2017, 13, e1006629.	2.1	44
148	HIV-specific CD8 T cells express low levels of IL-7RÎ±: Implications for HIV-specific T cell memory. Virology, 2006, 353, 366-373.	1.1	43
149	A New Glycan-Dependent CD4-Binding Site Neutralizing Antibody Exerts Pressure on HIV-1 In Vivo. PLoS Pathogens, 2015, 11, e1005238.	2.1	43
150	HIV Control through a Single Nucleotide on the HLA-B Locus. Journal of Virology, 2012, 86, 11493-11500.	1.5	41
151	The Breadth of Expandable Memory CD8 ⁺ T Cells Inversely Correlates with Residual Viral Loads in HIV Elite Controllers. Journal of Virology, 2015, 89, 10735-10747.	1.5	41
152	A Reproducibility-Based Computational Framework Identifies an Inducible, Enhanced Antiviral State in Dendritic Cells from HIV-1 Elite Controllers. Genome Biology, 2018, 19, 10.	3.8	37
153	Virus-driven Inflammation Is Associated With the Development of bNAbs in Spontaneous Controllers of HIV. Clinical Infectious Diseases, 2017, 64, 1098-1104.	2.9	36
154	Temporal changes in T cell subsets and expansion of cytotoxic CD4+ T cells in the lungs in severe COVID-19. Clinical Immunology, 2022, 237, 108991.	1.4	36
155	A Cure for HIV Infection: â€œNot in My Lifetimeâ€•or â€œJust Around the Cornerâ€?. Pathogens and Immunity, 2016, 1, 154.	1.4	35
156	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. Journal of Virology, 2014, 88, 10200-10213.	1.5	33
157	Toward T Cell-Mediated Control or Elimination of HIV Reservoirs: Lessons From Cancer Immunology. Frontiers in Immunology, 2019, 10, 2109.	2.2	32
158	HIV-infected macrophages resist efficient NK cell-mediated killing while preserving inflammatory cytokine responses. Cell Host and Microbe, 2021, 29, 435-447.e9.	5.1	32
159	Reconstitution of Virus-Specific CD4 Proliferative Responses in Pediatric HIV-1 Infection. Journal of Immunology, 2003, 171, 6968-6975.	0.4	31
160	High Avidity CD8+ T Cells Efficiently Eliminate Motile HIV-Infected Targets and Execute a Locally Focused Program of Anti-Viral Function. PLoS ONE, 2014, 9, e87873.	1.1	31
161	Role of HIV-specific CD8+ T cells in pediatric HIV cure strategies after widespread early viral escape. Journal of Experimental Medicine, 2017, 214, 3239-3261.	4.2	31
162	Viral control in chronic HIV-1 subtype C infection is associated with enrichment of p24 IgG1 with Fc effector activity. Aids, 2018, 32, 1207-1217.	1.0	31

#	Article	IF	Citations
163	Evolution and Diversity of Immune Responses during Acute HIV Infection. Immunity, 2020, 53, 908-924.	6.6	31
164	Metabolic pathway activation distinguishes transcriptional signatures of CD8+ T cells from HIV-1 elite controllers. Aids, 2018, 32, 2669-2677.	1.0	30
165	Mosaic HIV-1 Gag Antigens Can Be Processed and Presented to Human HIV-Specific CD8+ T Cells. Journal of Immunology, 2011, 186, 6914-6924.	0.4	29
166	HIV-1 Antibody Neutralization Breadth Is Associated with Enhanced HIV-Specific CD4 ⁺ T Cell Responses. Journal of Virology, 2016, 90, 2208-2220.	1.5	29
167	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. Clinical Infectious Diseases, 2017, 64, ciw833.	2.9	28
168	Nanoscale imaging of clinical specimens using conventional and rapid-expansion pathology. Nature Protocols, 2020, 15, 1649-1672.	5.5	28
169	CD8 ⁺ T Cell Breadth and Ex Vivo Virus Inhibition Capacity Distinguish between Viremic Controllers with and without Protective HLA Class I Alleles. Journal of Virology, 2016, 90, 6818-6831.	1.5	27
170	Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. Journal of Clinical Investigation, 2021, 131, .	3.9	27
171	HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Seminars in Immunopathology, 1997, 18, 341-354.	4.0	26
172	Differential Ability of Primary HIV-1 Nef Isolates To Downregulate HIV-1 Entry Receptors. Journal of Virology, 2015, 89, 9639-9652.	1.5	26
173	Elite controller CD8+ T cells exhibit comparable viral inhibition capacity, but better sustained effector properties compared to chronic progressors. Journal of Leukocyte Biology, 2016, 100, 1425-1433.	1.5	24
174	HIV Controllers Exhibit Enhanced Frequencies of Major Histocompatibility Complex Class II Tetramer⁺Gag-Specific CD4⁺T Cells in Chronic Clade C HIV-1 Infection. Journal of Virology, 2017, 91, .	1.5	24
175	Relative Resistance of HLA-B to Downregulation by Naturally Occurring HIV-1 Nef Sequences. MBio, 2016, 7, e01516-15.	1.8	23
176	The complex and specific pMHC interactions with diverse HIV-1 TCR clonotypes reveal a structural basis for alterations in CTL function. Scientific Reports, 2014, 4, 4087.	1.6	22
177	Crystal structure of HLA-B*5801 with a TW10 HIV Gag epitope reveals a novel mode of peptide presentation. Cellular and Molecular Immunology, 2017, 14, 631-634.	4.8	22
178	A FRESH approach: Combining basic science and social good. Science Immunology, 2018, 3, .	5.6	22
179	HIV Controllers Exhibit Effective CD8+ T Cell Recognition of HIV-1-Infected Non-activated CD4+ T Cells. Cell Reports, 2019, 27, 142-153.e4.	2.9	22
180	Immunological Fingerprints of Controllers Developing Neutralizing HIV-1 Antibodies. Cell Reports, 2020, 30, 984-996.e4.	2.9	22

#	Article	IF	Citations
181	Nef-mediated down-regulation of CD4 and HLA class I in HIV-1 subtype C infection: Association with disease progression and influence of immune pressure. Virology, 2014, 468-470, 214-225.	1.1	20
182	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. Journal of Infectious Diseases, 2017, 216, 1063-1069.	1.9	20
183	Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infectious Diseases, 2021, 8, ofab153.	0.4	20
184	Functional impairment of HIV-specific CD8+ TÂcells precedes aborted spontaneous control of viremia. Immunity, 2021, 54, 2372-2384.e7.	6.6	20
185	HIV Subtype Influences HLA-B*07:02-Associated HIV Disease Outcome. AIDS Research and Human Retroviruses, 2014, 30, 468-475.	0.5	19
186	Sex Differences in Antiretroviral Therapy Initiation in Pediatric HIV Infection. PLoS ONE, 2015, 10, e0131591.	1.1	19
187	Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses. Journal of Virology, 2016, 90, 8605-8620.	1.5	18
188	Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. Cell Reports, 2019, 29, 1449-1457.e5.	2.9	18
189	Inhibition of Human Immunodeficiency Virus Type 1 Replication in Primary CD4+ T Lymphocytes, Monocytes, and Dendritic Cells by Cytotoxic T Lymphocytes. Journal of Virology, 2000, 74, 6695-6699.	1.5	17
190	Motif Inference Reveals Optimal CTL Epitopes Presented by HLA Class I Alleles Highly Prevalent in Southern Africa. Journal of Immunology, 2006, 176, 4699-4705.	0.4	17
191	HLA class-I-peptide stability mediates CD8+ TÂcell immunodominance hierarchies and facilitates HLA-associated immune control of HIV. Cell Reports, 2021, 36, 109378.	2.9	17
192	AIDS Vaccine Development. Science, 1998, 280, 803c-803.	6.0	16
193	T cell receptors for the HIV KK10 epitope from patients with differential immunologic control are functionally indistinguishable. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1877-1882.	3.3	15
194	High Frequency of Transmitted HIV-1 Gag HLA Class I-Driven Immune Escape Variants but Minimal Immune Selection over the First Year of Clade C Infection. PLoS ONE, 2015, 10, e0119886.	1.1	14
195	HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. MBio, 2021, 12, e0249021.	1.8	14
196	Epitope convergence of broadly HIV-1 neutralizing IgA and IgG antibody lineages in a viremic controller. Journal of Experimental Medicine, 2022, 219, .	4.2	14
197	Modest Attenuation of HIV-1 Vpu Alleles Derived from Elite Controller Plasma. PLoS ONE, 2015, 10, e0120434.	1.1	13
198	Population-Level Immune-Mediated Adaptation in HIV-1 Polymerase during the North American Epidemic. Journal of Virology, 2016, 90, 1244-1258.	1.5	13

#	Article	IF	Citations
199	Concanamycin A counteracts HIV-1 Nef to enhance immune clearance of infected primary cells by cytotoxic T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 23835-23846.	3.3	12
200	An HLA-I signature favouring KIR-educated Natural Killer cells mediates immune control of HIV in children and contrasts with the HLA-B-restricted CD8+ T-cell-mediated immune control in adults. PLoS Pathogens, 2021, 17, e1010090.	2.1	12
201	T-Cell Receptor (TCR) Clonotype-Specific Differences in Inhibitory Activity of HIV-1 Cytotoxic T-Cell Clones Is Not Mediated by TCR Alone. Journal of Virology, 2017, 91, .	1.5	11
202	Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. EBioMedicine, 2021, 63, 103175.	2.7	10
203	Allelic variation in class I HLA determines CD8 T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Science Immunology, 2021, , eabk3070.	5.6	10
204	CD8 lymphocytes mitigate HIV-1 persistence in lymph node follicular helper T cells during hyperacute-treated infection. Nature Communications, 2022, 13, .	5.8	10
205	A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. Journal of Experimental Medicine, 2021, 218, .	4.2	9
206	Marked Differences in Quantity of Infectious Human Immunodeficiency Virus Type 1 Detected in Persons with Controlled Plasma Viremia by a Simple Enhanced Culture Method. Journal of Clinical Microbiology, 2000, 38, 4246-4248.	1.8	9
207	HLA-A*68. Aids, 2013, 27, 1717-1723.	1.0	7
208	Crystal structure of HLA-B*5801, a protective HLA allele for HIV-1 infection. Protein and Cell, 2016, 7, 761-765.	4.8	7
209	Impact of HLA Allele-KIR Pairs on HIV Clinical Outcome in South Africa. Journal of Infectious Diseases, 2019, 219, 1456-1463.	1.9	7
210	The AMP Trials â€" A Glass Half Full. New England Journal of Medicine, 2021, 384, 1068-1069.	13.9	7
211	Lower Viral Loads and Slower CD4⁺T-Cell Count Decline in MRKAd5 HIV-1 Vaccinees Expressing Disease-Susceptible HLA-B*58:02. Journal of Infectious Diseases, 2016, 214, 379-389.	1.9	6
212	Hypermethylation at the CXCR5 gene locus limits trafficking potential of CD8+ T cells into B-cell follicles during HIV-1 infection. Blood Advances, 2022, 6, 1904-1916.	2.5	6
213	Envelope characteristics in individuals who developed neutralizing antibodies targeting different epitopes in HIV-1 subtype C infection. Virology, 2020, 546, 1-12.	1.1	5
214	Multimodal Investigation of Neuroinflammation in Aviremic Patients With HIV on Antiretroviral Therapy and HIV Elite Controllers. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	3.1	5
215	Epigenetic Regulation of BST-2 Expression Levels and the Effect on HIV-1 Pathogenesis. Frontiers in Immunology, 2021, 12, 669241.	2.2	4
216	CD8 + T Cells and cART: A Dynamic Duo?. Immunity, 2016, 45, 466-468.	6.6	2

#	Article	IF	Citations
217	Saporin-conjugated tetramers identify efficacious anti-HIV CD8+ T-cell specificities. PLoS ONE, 2017, 12, e0184496.	1.1	2
218	CMV, MHC-E, and the quest for an unconventional AIDS vaccine. Science Immunology, 2021, 6, .	5.6	2
219	A Leucine Zipper Dimerization Strategy to Generate Soluble T Cell Receptors Using the Escherichia coli Expression System. Cells, 2022, 11, 312.	1.8	2
220	AIDS Vaccines. , 2016, , 401-422.		1
221	HIV controllers: an untapped source of clues to overcoming HIV infection. Research Initiative, Treatment Action: RITA, 2007, 12, 21-2.	0.1	1
222	Dendritic Cells from HIV-1 Neutralizers Efficiently Induce the Generation of CXCR5+ CXCR3+ PD1Lo CD4 T Cells with B Cell Helper Function. AIDS Research and Human Retroviruses, 2014, 30, A74-A74.	0.5	0